Patents by Inventor J. Tso

J. Tso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED ANTIBODIES AGAINST CD3
    Publication number: 20080025975
    Abstract: The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.
    Type: Application
    Filed: March 26, 2007
    Publication date: January 31, 2008
    Applicants: Protein Design Labs, Inc., Iowa Immunotherapy Investigators
    Inventors: George Weiner, Roger Gingrich, Brian Link, J. Tso
  • Therapeutic use of anti-CS1 antibodies
    Publication number: 20060024296
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: November 5, 2004
    Publication date: February 2, 2006
    Applicant: Protein Design Labs, Inc.
    Inventors: Marna Williams, J. Tso, Nicholas Landolfi, David Powers, Robert DuBridge, Debbie Law, Gao Liu
  • Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
    Publication number: 20050276799
    Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
    Type: Application
    Filed: April 8, 2005
    Publication date: December 15, 2005
    Inventors: Paul Hinton, Naoya Tsurushita, J. Tso, Maximiliano Vasquez
  • Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
    Publication number: 20050032114
    Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
    Type: Application
    Filed: October 15, 2003
    Publication date: February 10, 2005
    Inventors: Paul Hinton, Naoya Tsurushita, J. Tso, Maximiliano Vasquez
  • Therapeutic use of anti-CS1 antibodies
    Publication number: 20050025763
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: May 7, 2004
    Publication date: February 3, 2005
    Applicant: Protein Design Laboratories, Inc.
    Inventors: Marna Williams, J. Tso, Nicholas Landolfi
  • Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
    Publication number: 20050014934
    Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
    Type: Application
    Filed: April 9, 2004
    Publication date: January 20, 2005
    Inventors: Paul Hinton, Naoya Tsurushita, J. Tso, Maximiliano Vasquez